Zanubrutinib switch in patients with previously treated B-cell malignancies intolerant to previous Bruton tyrosine kinase inhibitors: Final results of a phase 2, open-label, single-arm study

ASH 2026 • B-cell malignancies • Zanubrutinib • Poster

Mazyar Shadman, MD MPH

DISCLAIMER

The contents of the presentation are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and/or efficacy for such investigational products or uses may be made.

SUMMARY

BGB-3111-215 was a phase 2, open-label, single-arm, multicenter study designed to evaluate the safety and efficacy of zanubrutinib in adults with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström macroglobulinemia, mantle cell lymphoma, or marginal zone lymphoma who were intolerant to prior Bruton tyrosine kinase inhibitor therapy. The final analysis (data cutoff: January 9, 2026) is reported here. A total of 96 patients were enrolled (Cohort 1 [ibrutinib-intolerant]: n=57; Cohort 2 [acalabrutinib-intolerant]: n=39, including 14 intolerant to both). Median zanubrutinib treatment duration was 44.4 months in Cohort 1 and 22.1 months in Cohort 2. Across both cohorts, 62% of prior intolerance events did not recur with zanubrutinib (Cohort 1: 78/125; Cohort 2: 34/55), and no events recurred at higher severity. More than half of patients (Cohort 1: 52%; Cohort 2: 54%) had no recurrence of prior intolerance events. Overall, seven patients discontinued zanubrutinib because of recurrent intolerance events. Only 1 of 13 prior atrial fibrillation/flutter intolerance events recurred following the switch to zanubrutinib. Safety data were consistent with the known zanubrutinib profile. Across B-cell malignancies, the overall response rate was 66.7%, and disease control rate was 93.8%. With median follow-up of 44.2 months, median progression-free survival was not reached, and the estimated 48-month event-free rate was 71.6%. 

ClinicalTrials.gov ID: NCT04116437

Population Intervention / Exposure Comparator Outcomes
Adults in the United States with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström macroglobulinemia, mantle cell lymphoma, or marginal zone lymphoma who were intolerant to ibrutinib and/or acalabrutinib Zanubrutinib N/A
  • Primary endpoint: recurrence and change in severity of prior Bruton tyrosine kinase inhibitor therapy intolerance adverse events. 
  • Secondary outcomes: overall response, disease control, progression-free survival, and safety.

FAQs

BGB-3111-215 evaluated the safety and efficacy of zanubrutinib in patients with previously treated B-cell malignancies (chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenström macroglobulinemia, mantle cell lymphoma, or marginal zone lymphoma) who were intolerant to prior Bruton tyrosine kinase inhibitor (BTKi) therapy (ibrutinib and/or acalabrutinib), reporting final results from the phase 2, open-label, single-arm, multicenter study.

BGB-3111-215 was a phase 2, open-label, single-arm, multicenter trial. Patients intolerant to ibrutinib but not acalabrutinib were assigned to Cohort 1; patients intolerant to acalabrutinib (regardless of ibrutinib intolerance status) were assigned to Cohort 2. Patients received oral zanubrutinib 160 mg twice daily or 320 mg once daily, based on investigator and patient preference, until disease progression, unacceptable toxicity, withdrawal, or study termination. The primary endpoint was recurrence and change in severity of prior BTKi intolerance adverse events. Secondary outcomes included overall response rate (ORR), disease control rate (DCR; proportion achieving best overall response of stable disease or better before initiating subsequent anticancer therapy), and progression-free survival (PFS).

A total of 96 patients were enrolled (Cohort 1: n=57; Cohort 2: n=39, including 14 intolerant to both ibrutinib and acalabrutinib). Median prior BTKi treatment duration was 9.8 months in Cohort 1 (ibrutinib) and 6.3 months in Cohort 2 (acalabrutinib). Median zanubrutinib treatment duration was 44.4 months in Cohort 1 and 22.1 months in Cohort 2. Most patients ended study treatment due to sponsor-initiated study termination (Cohort 1: 52.6%; Cohort 2: 61.5%).

Across both cohorts, 62% of prior intolerance events did not recur with zanubrutinib (Cohort 1: 78/125; Cohort 2: 34/55), and no events recurred at higher severity. In Cohort 1, 68.1% (32/47) of prior intolerance events occurred at a lower severity on zanubrutinib; in Cohort 2, 38.1% (8/21) occurred at a lower severity. Over half of patients in each cohort had no recurrence of prior intolerance events (Cohort 1: 52% [36/69]; Cohort 2: 54% [21/39]). Ibrutinib intolerance events with low recurrence during zanubrutinib included atrial fibrillation/flutter (1/11), stomatitis (1/6), and muscle spasms (1/5). For acalabrutinib, a low rate of recurrence was observed for headache (1/7), and no atrial fibrillation/flutter or asthenia events recurred (0/2 each). 

 

Among ibrutinib-intolerant patients (Cohort 1), intolerance events with high rates of recurrence on zanubrutinib (rate ≥50% in events occurring in ≥5 patients during prior treatment) included hemorrhage (5/6), fatigue (9/14), arthralgia (5/10), and rash (5/10). Among acalabrutinib-intolerant patients (Cohort 2), events with high recurrence rates included diarrhea (3/3), hemorrhage (3/3), rash (3/4), myalgia (5/8), and fatigue (2/4). Only 1 of 13 prior atrial fibrillation/flutter intolerance events recurred following transition to zanubrutinib. 

 

Seven patients discontinued zanubrutinib due to recurrence of prior intolerance events (from ibrutinib: stomatitis, lymphoedema, hemorrhage; from acalabrutinib: rash [n=2], myalgia; from both: diarrhea).

Across B-cell malignancies, the ORR was 66.7% and DCR was 93.8%. With a median follow-up of 44.2 months (range, not reported), median PFS was not reached, and the estimated event-free rate at 48 months was 71.6%.

Safety data across both cohorts were consistent with the known zanubrutinib profile. Among ibrutinib-intolerant patients (Cohort 1), intolerance events with high rates of recurrence on zanubrutinib (rate ≥50% in events occurring in ≥5 patients during prior treatment) included hemorrhage (5/6), fatigue (9/14), arthralgia (5/10), and rash (5/10). Among acalabrutinib-intolerant patients (Cohort 2), events with high recurrence rates included diarrhea (3/3), hemorrhage (3/3), rash (3/4), myalgia (5/8), and fatigue (2/4). Only 1 of 13 prior atrial fibrillation/flutter intolerance events recurred following transition to zanubrutinib. Overall, seven patients discontinued zanubrutinib due to recurrence of prior intolerance events.

You are now leaving the website

This link is provided for information purposes only. You’ll be leaving beonemedaffairs.com and accessing a third-party website over which [BeOne Medicines | GmbH] has no control or influence.

This link will take you to a third-party website outside of beonemedaffairs.com.

[BeOne Medicines | GmbH] has no control over this website and makes no representations regarding its content or availability in your location. [BeOne Medicines | GmbH] declines any responsibility for third-party information, data usage policies, or personal data processing.

By proceeding, you acknowledge that you are part of the intended audience of the third-party website and confirm your compliance with applicable laws.

Do you want to leave beonemedaffairs.com

You are now leaving the website beonemedaffairs.com and entering another BeOne website with different terms of use. Information included on this website may not be specific to your country. Click Continue to proceed